Clinical Trial Update: Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a triple combination of recombinant Erwinia asparaginase, venetoclax, and blinatumomab for relapsed or refractory CD19-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd19-positive B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• Recombinant Erwinia asparaginase (Erwinia asparaginase)
• Venetoclax (venetoclax)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING